Journal of Clinical Oncology
Articles in this Issue
Efficacy and safety of second-line cabozantinib ± atezolizumab for patients with advanced renal cell carcinoma after progression on immuno-oncology combinations: Subgroup analysis of CONTACT-03.
4523 Background: Cabozantinib (cabo), a vascular endothelial growth factor receptor-associated tyrosine kinase inhibitor (TKI), is a preferred treatment o...
Frailty assessment in patients with advanced/metastatic renal cell carcinoma using routine data collected during treatment with tyrosine kinase inhibitors in the STAR trial.
4531 Background: The STAR trial (ISRCTN06473203) was a phase 2/3 randomised controlled non-inferiority trial (N=920) which assessed whether treatment brea...
Enhancing educational experiences through standardization of inpatient hematology curriculums.
9024 Background: Comprehensive hematology education during fellowship is essential for delivering high-quality healthcare. Variability in individual learn...
Effect of co-inheritance of KMT2C germline mutations on the phenotype of MSI-L/MSS Lynch syndrome patients.
e15085 Background: Germline mutations in MSH6 account for approximately 10–20% of all Lynch syndrome (LS) cases. MSH6 mutation carriers typically exhibit...
Liquid biopsy NGS as a longitudinal follow up tool in the clinical management of OSCC.
e18156 Background: Oral squamous cell carcinoma constitutes one of the major sites of head and neck cancer. Early detection of these cancers is known to h...
Efficacy and safety of combination therapy versus monotherapy in advanced non-small cell lung cancer: A meta-analysis of overall survival and progression-free survival.
e20612 Background: Combination therapies, such as immune checkpoint inhibitors (ICIs) with chemotherapy or EGFR-TKI-based combinations, improve outcomes f...
A retrospective study of anlotinib plus third-generation EGFR-TKIs in advanced non-small cell lung cancer with gradual or oligo progression after EGFR-TKIs treatment (ALTER-L058).
8600 Background: Despite the significant improvement in progression-free survival (PFS) for non-small cell lung cancer (NSCLC) patients with EGFR mutation...
Whole person cancer care: Analyzing patient needs and service utilization at Inova Schar Cancer.
e23216 Background: Whole person cancer care is an approach that addresses the comprehensive physical, emotional, social, and practical needs of cancer pat...
Impact of the lymphovascular invasion on the prognosis in pT1-2N0 early breast cancer.
e12517 Background: Lymphovascular invasion (LVI) has historically been considered a poor prognostic factor in breast cancer. However, the clinical impact...
Impact of pre-lymphodepletion (pre LD) and day 30 (M1) immune cell counts on outcomes of CAR T therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
7032 Background: The impact of immune cell counts pre LD and during immune reconstitution on CAR T therapy outcomes is poorly understood. We investigated...
Evaluating peripheral eosinophilia as a biomarker post CAR-T cell therapy.
e19085 Background: Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are early complications, while late...
Real-world clinical outcomes of capecitabine by BRCAm status in patients with early-stage triple-negative breast cancer.
e12503 Background: The clinical benefit of adjuvant capecitabine (cape) in patients (pts) with early triple-negative breast cancer (eTNBC) and...
Cancer misinformation and trust in doctors and scientists among cancer survivors.
11124 Background: Health misinformation is a significant public health concern and has acutely worsened in the past decade. Cancer survivors must navigate...
Predicting non-coding RNA-based regulatory networks in cancer metastasis using a heterogeneous hierarchical graph transformer.
e13663 Background: Advancements in high-throughput sequencing have enabled large-scale studies on the roles of non-coding RNAs (ncRNAs), including microRN...
Wilms tumor in Morocco: Epidemiology, challenges in management, and the promise of microRNAs as diagnosis biomarkers.
e22009 Background: Wilms tumor (WT) or nephroblastoma is the most common pediatric kidney cancer, accounting for 95% of renal tumors in children. Its diag...
A phase Ib clinical study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary anti-tumor efficacy of Hemay181 in patients with advanced solid tumors.
e15002 Background: Hemay181 is a broad-spectrum anti-tumor cytotoxic drug with tumor-targeting properties (about 44808 ASCO24). The prodrug conjugate is e...
First in human phase I study of TQB2103, a Claudin18.2 (CLDN18.2) targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors.
3026 Background: Claudin18.2 is a promising target for CLDN18.2-expressing cancers such as gastric and pancreatic cancers. TQB2103 is a novel ADC comprise...
Treatment strategies and outcomes of inflammatory myofibroblastic sarcoma: Insights from a retrospective single-center study.
e23540 Background: Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a rare, aggressive variant of inflammatory myofibroblastic tumor (IMT) that...
Exploring oncology clinician and staff experiences with substance use disorders among cancer patients.
e13821 Background: There is a rising rate of substance use disorders (SUD) among cancer patients in the United States. We explored the experiences, percep...
A real-world data claims-based review of CAR-T procedures, time to adverse events, patient characteristics and social factors.
11163 Background: With the increasing utilization of Chimeric antigen receptors T-cell therapies (CAR-T), administrative claims can provide insights into...
Clinical outcomes for Black patients with early-onset breast cancer: An analysis of the National Inpatient Sample.
11185 Background: Despite recent global decreases in overall cancer incidence, the incidence of early-onset breast cancer (EOBC) is steadily increasing gl...
Phase 1b dose extension study of a next-generation anti-CD47 monoclonal antibody IMC-002 combined with lenvatinib in patients with advanced hepatocellular carcinoma (HCC).
2526 Background: IMC-002 has shown significant preclinical efficacy and safety, which are attributed to its unique binding...
Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) plus leuprolide (combo): EMBARK post hoc analysis.
e17127 Background: In the phase 3 EMBARK trial, combo vs leuprolide alone meaningfully improved metastasis-free survival (primary endpoint) and secondary...
Ramucirumab in pediatric and young adult patients (Pts) with relapsed/refractory (R/R) desmoplastic small round cell tumor (DSRCT) or synovial sarcoma (SS): Results from the CAMPFIRE study.
11574 Background: Few effective therapies exist for pts with R/R DSRCT and SS, and hence, their prognosis remains poor. Preclinical data suggested the rel...
Toripalimab plus docetaxel, oxaliplatin, and capecitabine for untreated metastatic gastric and esophagogastric junction adenocarcinoma: A TORNADO study.
e16004 Background: Chemotherapy and PD-1 inhibitor have shown significant clinical benefits in first-line treatment of metastatic gastric and esophagogast...